Elutia Inc. (ELUT)
ELUT Stock Price Chart
Explore Elutia Inc. interactive price chart. Choose custom timeframes to analyze ELUT price movements and trends.
ELUT Company Profile
Discover essential business fundamentals and corporate details for Elutia Inc. (ELUT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2020
Employees
51.00
Website
https://elutia.comCEO
C. Randal Mills
Description
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
ELUT Financial Timeline
Browse a chronological timeline of Elutia Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 4 Mar 2026
Upcoming earnings on 13 Nov 2025
Revenue estimate is $6.90M.
Earnings released on 14 Aug 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $6.26M , missing expectations by -15.36%.
Earnings released on 8 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $6.03M , missing expectations by -9.32%.
Earnings released on 6 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $5.47M , missing expectations by -7.32%.
Earnings released on 14 Nov 2024
EPS came in at -$0.33 surpassing the estimated -$0.44 by +25.00%, while revenue for the quarter reached $5.92M , missing expectations by -7.47%.
Earnings released on 7 Aug 2024
EPS came in at -$1.14 falling short of the estimated -$0.33 by -245.45%, while revenue for the quarter reached $6.29M , missing expectations by -5.40%.
Earnings released on 9 May 2024
EPS came in at -$0.75 falling short of the estimated -$0.41 by -82.93%, while revenue for the quarter reached $6.69M , beating expectations by +9.74%.
Earnings released on 7 Mar 2024
EPS came in at -$0.66 falling short of the estimated -$0.28 by -135.71%, while revenue for the quarter reached $5.88M , missing expectations by -10.31%.
Earnings released on 13 Nov 2023
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $6.13M , missing expectations by -16.07%.
Earnings released on 14 Aug 2023
EPS came in at -$0.65 falling short of the estimated -$0.29 by -124.14%, while revenue for the quarter reached $10.30M , missing expectations by -17.63%.
Earnings released on 10 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.54 by +9.26%, while revenue for the quarter reached $13.05M , missing expectations by -4.74%.
Earnings released on 22 Mar 2023
EPS came in at -$0.38 surpassing the estimated -$0.69 by +44.93%, while revenue for the quarter reached $12.67M , beating expectations by +0.92%.
Earnings released on 29 Sept 2022
EPS came in at -$0.73 falling short of the estimated -$0.67 by -9.09%, while revenue for the quarter reached $12.39M , beating expectations by +0.09%.
Earnings released on 29 Jun 2022
EPS came in at -$0.69 , while revenue for the quarter reached $12.64M .
Earnings released on 30 Mar 2022
EPS came in at -$0.60 falling short of the estimated -$0.56 by -7.68%, while revenue for the quarter reached $11.50M , missing expectations by -0.78%.
Earnings released on 30 Dec 2021
EPS came in at -$0.82 , while revenue for the quarter reached $10.86M .
Earnings released on 29 Sept 2021
EPS came in at -$0.81 , while revenue for the quarter reached $11.49M .
ELUT Stock Performance
Access detailed ELUT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.